[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-adenoma":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,49,91,117,149,182,203,223,247,270,305,330,357,385,407,431,449,482,508,529,548,574,596,617,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605424","bile-acid-gut-microbiome-axis-modification-through-diet-education-for-colorectal-cancer-prevention-100605424",false,"NCT07162337","BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention","BILMOD: BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention","BILMOD","Inclusion Criteria:\n\n* Underwent screening or surveillance colonoscopy with removal of at least one adenoma.\n* Age 18-80 years.\n* Habitually consume a Western pattern diet.\n* BMI of at least 18.5 kg\u002Fm2 but less than 35 kg\u002Fm2\n* Weight stable in last 3 months (loss or gain \\\u003C4%).\n* Subjects must be able and willing to follow study procedures and instructions.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Strict dietary patterns (e.g., vegan, carnivore, kosher, low-carb etc.).\n* Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis.\n* Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of nonmelanoma skin) in which there has been any active treatment within the last three years.\n* Known diagnosis of Familial Adenomatous Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC, Lynch Syndrome).\n* Any adenoma that was not completely removed during previous colonoscopy.\n* Known bleeding tendency\u002Fcondition (e.g. von Willebrand disease) or history of peptic ulcer or gastrointestinal bleed requiring hospitalization, endoscopic complications, or contraindication to colonoscopy.\n* Current use of anticoagulant therapies, including Heparin, Warfarin, Dalteparin sodium, Bivalirudin, Argatroban, Lepirudin, Heparin Sodium, Heparin\u002FDextrose, and an unwillingness or inability to discontinue anticoagulants.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Regular use of aspirin.\n* Use of antibiotics or probiotics.\n* Inability or unwillingness to abstain from limited consumption of animal-based food or to provide blood or stool samples during the study.\n* Participants who are receiving any other investigational agents.\n* Pregnant or breastfeeding.\n* Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.","ALL","18 Years","80 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer.",[29,30],"Colorectal Cancer Prevention","Colorectal Adenoma",[32,33,34,35,36],"colorectal cancer","colorectal cancer prevention","colorectal adenoma","obesity","western diet","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":38,"type":41},{"date":44,"type":23},"2028-06-01",{"name":46,"class":47},"Massachusetts General Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":69,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":48},"100617125","recurrence-after-gastric-and-intestinal-polyp-resection-100617125","NCT07314554","Recurrence After Gastric and Intestinal Polyp Resection","Recurrence Rate and Risk Factors After Endoscopic Resection of Gastric and Intestinal Polyps: A Retrospective and Prospective Cohort Study","RAGIP","Inclusion Criteria:\n\n* Age 18 years or older\n* First-time endoscopic examination (gastroscopy or colonoscopy) at the study center\n* Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)\n* Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)\n* Negative resection margins or complete resection assessed by pathology\n* At least one follow-up endoscopic examination completed (for retrospective cohort) or willingness to complete follow-up (for prospective cohort)\n* Complete baseline clinical data available\n\nExclusion Criteria:\n\n* Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)\n* Inflammatory bowel disease (ulcerative colitis or Crohn's disease)\n* Previous history of gastric or colorectal cancer\n* Cancer detected at initial resection (stage T1b or higher)\n* Non-polyp pathology (e.g., submucosal tumors, normal mucosa)\n* Incomplete resection with positive margins that were not re-treated\n* Lost to follow-up with no available surveillance data (for retrospective cohort)\n* Pregnancy at time of enrollment\n* Inability or unwillingness to provide informed consent (for prospective cohort)",{"count":58,"type":23},2000,"3 Years","OBSERVATIONAL","This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.\n\nBACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.\n\nOBJECTIVES:\n\nPrimary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model\n\nDESIGN: Mixed retrospective-prospective cohort study\n\n* Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024\n* Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028\n\nSETTING: Single tertiary referral center with \\>10,000 endoscopic polyp resections performed since 2021\n\nPARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps\n\nFOLLOW-UP:\n\n* Short-term: 1 year post-resection (±2 months)\n* Long-term: 3 years post-resection (±3 months)\n\nMAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance\n\nPOTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use\n\nEXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.",[63,64,65,66,67,68,30],"Gastric Polyps","Intestinal Polyps","Colon Polyps","Colorectal Polyps","Adenomatous Polyps","Gastric Adenoma and Early Gastric Cancer",[70,71,72,73,74,75,76,77,78,79,80],"Polyp recurrence","Endoscopic resection","Polypectomy","Endoscopic mucosal resection","Endoscopic submucosal dissection","Risk factors","Surveillance","Follow-up","Adenoma","Gastric polyp","Colorectal polyp","NOT_YET_RECRUITING","2026-06-07",{"date":84,"type":41},"2026-06-09",{"date":86,"type":23},"2026-07-26",{"date":88,"type":23},"2029-02-25",{"name":90,"class":47},"LanZhou University",{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100605809","phase-4-the-effect-of-oral-clostridium-butyricum-on-the-recurrence-after-colonoscopic-resection-of-colorectal-adenoma-100605809","NCT07167342","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma","The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma - A Multicenter, Double-blinded, Differential Design, Randomized, Placebo-controlled Study","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* No restriction on sex\n* Boston Bowel Preparation Score (BBPS) ≥ 7 prior to endoscopic procedure\n* Completed endoscopic resection of colorectal adenomas (including cold snare polypectomy, ESD, EMR, etc.) with no residual adenomas or polyps observed endoscopically\n* Histologically confirmed adenomas (including tubular, villous, or tubulovillous types) without malignant transformation\n* Able to take oral medication\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, prebiotics, synbiotics, or antibiotics within 2 weeks prior to enrollment\n* Presence of psychiatric disorders or other conditions preventing compliance with the intervention\n* Dysfunction of vital organs (liver, kidney, heart, etc.) deemed unsuitable for clinical study participation after evaluation\n* Participation in other clinical trials within 3 months prior to enrollment\n* History of gastrointestinal surgery (excluding endoscopic procedures)\n* History of inflammatory bowel disease\n* History of autoimmune diseases\n* Long-term use of aspirin (≥100 mg\u002Fday for over 3 months) or calcium supplements (≥1200 mg\u002Fday for over 3 months)\n* Pregnancy or breastfeeding\n* Previous treatment for colorectal adenomas (including endoscopic or surgical resection)\n* Familial adenomatous polyposis (FAP)","75 Years",{"count":100,"type":23},294,[102],"PHASE4","The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.",[30,105],"Probiotics",[30,107],"Clostridium butyricum","2026-05-22",{"date":110,"type":41},"2026-05-26",{"date":108,"type":41},{"date":113,"type":23},"2030-04-30",{"name":115,"class":47},"The Affiliated Hospital of Qingdao University",2,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":24,"phases":129,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":148},"100486305","colonoscopy-vs-stool-testing-for-older-adults-with-colon-polyps-100486305","NCT05612347","Colonoscopy vs Stool Testing for Older Adults With Colon Polyps","Colonoscopy Versus Stool-based Testing for Older Adults With a History of Colon Polyps","COOP","Inclusion Criteria:\n\n* English or Spanish speaking\n* Personal history of colorectal polyps\n* Most recent colonoscopy with ≤2 non-advanced polyps\n* Currently due or coming due within 12 months for colonoscopy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer\n* Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome)\n* Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease)\n* Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps\n* Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year)\n* Patients unable to provide written informed consent","65 Years","82 Years",{"count":128,"type":23},8946,[26],"This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.",[132,133,30,134,135],"Colorectal Polyp","Colorectal Neoplasms","Colorectal Cancer","Digestive System Disease",[137,138],"Colonoscopy","Fecal immunochemical test (FIT)","2026-05-01",{"date":141,"type":41},"2026-05-07",{"date":143,"type":41},"2023-06-14",{"date":145,"type":23},"2035-12-31",{"name":147,"class":47},"Dartmouth-Hitchcock Medical Center",22,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":157,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":24,"phases":160,"briefSummary":161,"conditions":162,"keywords":169,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":181},"100526334","paradigm---en-bloc-trial-with-the-endoquest-endoluminal-surgical-els-system-100526334","NCT06133387","PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System","PARADIGM Study: Prospective Assessment of a Robotic Assisted Device in Gastrointestinal Medicine - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System","PARADIGM","Preoperative Inclusion Criteria:\n\n1. Subject is ≥22 years at the time of consent.\n2. Subject has a BMI ≤ 50 kg\u002Fm2.\n3. Subject has an ASA score of ≤ 3.\n4. Subject has benign lesion(s) of the rectum or sigmoid colon, such as adenoma (with low- or high-grade dysplasia), neuroendocrine tumor, or other type of polyp as assessed by the most recent colonoscopy\u002Fflexible sigmoidoscopy.\n5. Subject has lesion ≤ 7 cm in size (dimension of greatest extent) and ≤ 75% of the colorectal circumference as assessed by the most recent colonoscopy\u002Fflexible sigmoidoscopy.\n6. Subject is eligible for standard endoscopic submucosal dissection.\n7. Subject agrees to participate in the study by giving signed informed consent.\n\nPreoperative Exclusion Criteria:\n\n1. Subject anatomy is unsuitable for endoscopic visualization or endoluminal surgery.\n2. Subject has active left-sided inflammatory bowel disease.\n3. Subject has an untreated active infection at the time of the procedure.\n4. Subject is considered part of a vulnerable population (e.g., prisoners, mentally disabled).\n5. Subject has a severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions (e.g., cancer).\n6. Subject is breastfeeding or pregnant or intends to become pregnant during the study.\n7. Subject is currently enrolled in or discontinued within the last 30 days from a clinical trial of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.\n8. Subject with EF ≤ 45, high cardiac or high pulmonary risk (these subjects require clearance from a cardiologist and pulmonologist, as applicable).\n9. Subject on preoperative blood thinners, such as coumadin or heparin, that cannot be weaned prior to surgery.\n10. Subject is moderately or severely immunocompromised.\n11. In the opinion of the Investigator, the subject is unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.\n\nIntraoperative Exclusion Criteria (assessed with third-party endoscope):\n\n1. Inadequate bowel prep.\n2. Complex anatomical findings not feasible for an endoluminal approach.\n3. Anatomical narrowing distal to the lesion site.\n4. Lesion not located in the rectum or sigmoid colon.\n5. Lesion size \\>7 cm (dimension of greatest extent) or occupies \\>75% of the colorectal circumference.\n6. Lesion demonstrates characteristics indicative of invasive carcinoma, such as failure to lift upon submucosal injection, or any other features that raise the Investigator's suspicion of cancer.\n\n   Intraoperative Exclusion Criteria (assessed with study device):\n7. In the opinion of the Investigator, the subject and\u002For subject anatomy is not suitable for study device use for any reason.\n8. Lesion location not accessible by the study device.","22 Years",{"count":159,"type":23},56,[26],"The objective of this study is to evaluate the safety and effectiveness of the Endoluminal Surgical (ELS) System in subjects undergoing specified transanal endoluminal procedures in the rectum and sigmoid colon. Subjects will undergo endoscopic submucosal dissection (ESD), with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.\n\nThe safety and effectiveness outcomes will be assessed intraoperatively and postoperatively at discharge and Days 7 and 30.",[163,30,132,164,165,166,167,168],"Colorectal Lesion","Rectal Lesion","Rectal Adenoma","Rectal Polyp","Sigmoid; Lesion","Sigmoid Colon Polyp",[164,170],"Sigmoid Lesion","2026-04-09",{"date":173,"type":41},"2026-04-14",{"date":175,"type":41},"2025-05-13",{"date":177,"type":23},"2026-06",{"name":179,"class":180},"EndoQuest Robotics, Inc.","INDUSTRY",6,{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100631774","phase-3-jianpi-lishi-jiedu-granules-for-prevention-of-postoperative-recurrence-in-colorectal-advanced-adenomas-100631774","NCT07505056","Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas","A Multicenter, Randomized, Double-blind, Parallel-controlled Clinical Study on the Intervention of Jianpi Lishi Jiedu Granules for Postoperative Recurrence of Colorectal Advanced Adenomas","Inclusion Criteria:\n\n1. Aged between 18 and 80 years, male or female\n2. Have undergone endoscopic resection of colorectal adenoma within the past 2 weeks (cold snare resection or endoscopic mucosal resection for adenomas \\\u003C 20 mm, or endoscopic submucosal dissection for adenomas ≥ 20 mm), and have been diagnosed with colorectal advanced adenoma by endoscopy and pathology\n3. Traditional Chinese Medicine (TCM) syndrome type conforms to the Spleen Deficiency and Dampness Toxin syndrome\n4. The patient is fully informed, voluntarily consents to data collection, and has signed the informed consent form\n\nExclusion Criteria:\n\n1. Patients with diseases such as familial polyposis, inflammatory bowel disease, serrated polyposis syndrome, Peutz-Jeghers syndrome, or other hereditary polyposis syndromes\n2. Patients with long-term use of medications such as aspirin, metformin, intestinal flora regulators, folic acid, calcium preparations, and vitamin D\n3. Patients with a bleeding tendency (referring to a pathological state where hemostasis is difficult after spontaneous bleeding or minor trauma due to coagulation dysfunction or vascular structural issues) or those currently using anticoagulant medications (e.g., aspirin, clopidogrel)\n4. Patients in the active phase of inflammatory bowel disease (such as ulcerative colitis, Crohn's disease, etc.), with a history of intestinal bleeding, or a history of intestinal surgery\n5. Patients with high-grade intraepithelial neoplasia involving the vascular system, lymphatic tumor thrombi, or small arteries; patients with biopsy pathology confirming suspected malignancy or established malignancy\n6. Pregnant or lactating women, or patients planning a recent pregnancy\n7. Patients with an allergic constitution or a history of allergies to multiple drugs\n8. Patients with severe heart, brain, lung, liver, kidney diseases, or mental disorders who cannot tolerate colonoscopy, treatment, and clinical intervention\n9. Patients currently participating in other clinical trials or those previously involved in trials related to this study.",{"count":190,"type":23},376,[192],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Jianpi Lishi Jiedu Granules in preventing postoperative recurrence of colorectal advanced adenoma. A total of 376 patients aged 18-80 years with endoscopically resected advanced adenoma and diagnosed with Spleen Deficiency and Dampness Toxin syndrome will be enrolled and randomly assigned to receive either Jianpi Lishi Jiedu Granules or placebo for 3 months. The primary endpoint is the adenoma recurrence rate at 1 year post-treatment, assessed by colonoscopy and pathological examination. Secondary endpoints include malignant transformation rate, TCM syndrome improvement, quality of life, gastrointestinal symptoms, and exploratory analyses of gut microbiota and inflammatory cytokines.",[30],"2026-03-26",{"date":197,"type":41},"2026-04-01",{"date":139,"type":23},{"date":200,"type":23},"2028-02-29",{"name":202,"class":47},"Nanjing First Hospital, Nanjing Medical University",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":48},"100598587","application-evaluation-research-on-the-artificial-intelligence-assisted-support-system-for-the-diagnosis-of-colorectal-tubular-adenoma-lesions-100598587","NCT07073430","Application Evaluation Research on the Artificial Intelligence-assisted Support System for the Diagnosis of Colorectal Tubular Adenoma Lesions","Inclusion Criteria:\n\n* Patients aged ≥ 18 years, who need to undergo colonoscopy, regardless of gender.\n* Voluntarily sign the informed consent form\n* Promise to abide by the research procedures and cooperate in the implementation of the entire research process.\n\nExclusion Criteria:\n\n* Patients who has a history of abdominal or pelvic surgery or radiotherapy in the past;\n* Patients who has definite active lower gastrointestinal bleeding.\n* Existing or suspected hereditary colorectal polyposis, inflammatory bowel disease;\n* Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 95 mmHg after standardized treatment)\n* There is a history of stroke, coronary artery disease, or vascular disease;\n* Pregnant;\n* Intestinal preparation cannot be carried out.",{"count":210,"type":23},4000,"This study is a prospective,multi-center and observational clinical study.Investigators would like to innovatively construct a \"trinity\" database of colorectal tubular adenomas based on white light - magnifying chromo - pathological images.It simulates the decision - making logic of doctors, and based on the multimodal endoscopic LAFEQ method previously proposed, develop a multimodal deep - learning diagnostic model for colon adenomas and an interpretable risk prediction model for intestinal adenomas. While achieving high - precision auxiliary treatment decisions, clearly present the decision - making basis, and break through the limitation of poor interpretability of previous medical imaging AI models.",[30,213],"Artificial Intelligence (AI)","2026-03-21",{"date":216,"type":41},"2026-03-25",{"date":218,"type":41},"2023-11-28",{"date":220,"type":23},"2026-10-31",{"name":222,"class":47},"Renmin Hospital of Wuhan University",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":48},"100600286","phase-1-pathways-risk-factors-and-molecules-to-prevent-early-onset-colorectal-tumors-100600286","NCT07095517","Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","PROSPECT","Inclusion Criteria:\n\n* Age 18-50 years Because no dosing or adverse event data are currently available on the use of tirzepatide in participants \\\u003C18 years of age, children are excluded from this study. Because we are specifically studying the prevention of EOCRC, which is defined as CRC occurring prior to age 50, the study population will only enroll participants under the age of 50 at baseline.\n* BMI between 27 and 40 kg\u002Fm2\n* Underwent a screening or surveillance colonoscopy within the prior 9 months.\n* Removal of multiple (at least 2) colon or rectal adenomas (including sessile serrated adenomas but excluding hyperplastic polyps) or a single adenoma ≥6mm in size during the last colonoscopy\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have ever taken incretin mimetic therapies.\n* Participants with a history of medullary thyroid cancer or MEN 2 syndrome.\n* Participants at high risk of pancreatitis or otherwise contraindicated for use of tirzepatide according to clinical labeling.\n* Participants with a history of cancer (excluding non-melanoma skin) within the last three years\n* Participants with a history of diabetes mellitus\n* Participants with a history of bowel surgery\n* Participants with hereditary cancer syndromes, including HNPCC\u002FLynch syndrome or familial adenomatous polyposis\n* Participants with a history of inflammatory bowel disease, Crohn's, or colitis.\n* Participants with incomplete or partial polypectomy during prior colonoscopy.\n* Participants who are pregnant. Participants who may become pregnant or partners of those who may become pregnant while on study will receive contraception counseling. Participants or partners of those who become pregnant while participating on the study should immediately inform their doctor.","50 Years",{"count":232,"type":23},20,[234],"PHASE1","This research study is an open-label Phase 1 Exploratory\u002FPilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.",[29,30],[32,33,34,35,238],"incretin mimetics","2026-02-25",{"date":241,"type":41},"2026-02-27",{"date":243,"type":41},"2026-02-24",{"date":245,"type":23},"2028-12-31",{"name":46,"class":47},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":254,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":255,"targetDuration":257,"studyType":60,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":4},"100624508","quantitative-fecal-immunochemical-test-for-detection-of-colorectal-cancer-and-precancerous-lesions-in-sohag-100624508","NCT07410546","Quantitative Fecal Immunochemical Test for Detection of Colorectal Cancer and Precancerous Lesions in Sohag","Role of Quantitative Fecal Immunochemical Test as a Diagnostic Tool in Evaluation of Site and Type of Colorectal Cancer and Precancerous Lesions in Sohag Government","Inclusion Criteria:\n\n* Adults aged 40 to 75 years\n* Individuals undergoing screening or diagnostic colonoscopy\n* Participants able to provide informed consent\n\nExclusion Criteria:\n\n* Age below 40 years or above 75 years\n* History of colorectal surgery\n* Inflammatory bowel disease\n* Inadequate bowel preparation\n* Refusal to participate",true,{"count":256,"type":23},150,"1 Day","Colorectal cancer is a major cause of cancer-related morbidity and mortality worldwide, and early detection significantly improves patient outcomes. The fecal immunochemical test (FIT) is a non-invasive stool-based test used for detection of colorectal cancer; however, its diagnostic performance varies according to lesion type and anatomical location.\n\nThis prospective observational cohort study aims to evaluate the diagnostic accuracy of quantitative fecal immunochemical testing (qFIT) in detecting colorectal cancer and precancerous lesions, including advanced adenomas and sessile serrated lesions, in adults undergoing colonoscopy in Sohag Government. The study will assess the sensitivity, specificity, and optimal cutoff values of qFIT according to lesion type, location, and histopathological characteristics.",[134,30,260],"Sessile Serrated Lesion","2026-02-07",{"date":263,"type":41},"2026-02-13",{"date":265,"type":23},"2026-02",{"date":267,"type":23},"2026-08",{"name":269,"class":47},"Sohag University",{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":257,"studyType":60,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":48},"100621125","epigenetic-factors-of-colorectal-adenoma-in-korean-100621125","NCT07366554","Epigenetic Factors of Colorectal Adenoma in Korean","Exploration of Epigenetic Factors of Colorectal Adenoma in Korean","* Inclusion Criteria:\n\n  * Adults aged 19-85 years\n  * Undergoing colonoscopic polypectomy for colorectal adenoma\n  * Able to understand the study purpose and provide written informed consent\n  * Adequate tissue available for both adenoma and adjacent normal mucosa sampling\n* Exclusion Criteria:\n\n  * History of colorectal cancer, inflammatory bowel disease, or hereditary colorectal cancer syndrome (e.g., FAP, Lynch syndrome)\n  * Previous colorectal surgery that may alter anatomy or pathology\n  * Inadequate sample quality or failure of DNA extraction\n  * Refusal or withdrawal of informed consent\n  * Severe comorbidities that make participation unsuitable at investigator's discretion","19 Years","85 Years",{"count":280,"type":23},32,"This study aims to explore epigenetic factors associated with colorectal adenoma (CRA) in the Korean population. CRA is a key precancerous lesion in the adenoma-carcinoma sequence, and identifying methylated genetic markers may improve early detection and risk stratification for colorectal cancer (CRC).\n\nA total of 32 patients undergoing colonoscopic polypectomy will be enrolled. Adenomatous and adjacent normal tissues will be collected for deoxyribonucleic acid (DNA) extraction and bisulfite conversion. Quantitative methylation-specific polymerase chain reaction (qMSP) and Sanger sequencing will be used to assess the methylation status of candidate genes (SFRP2, TFPI2, SEPT9, and SDC2). Stool samples will also be analyzed by whole-genome sequencing (WGS) to evaluate microbiome and genetic profiles.\n\nThe study seeks to determine whether methylation levels of these genes are significantly elevated in adenoma tissue compared with normal mucosa, thereby identifying potential biomarkers for colorectal neoplasia surveillance and personalized colonoscopy follow-up intervals.",[30,283],"Colorectal Cancer Precancerous Lesion",[30,285,286,287,288,289,290,291,292,293,294,295],"DNA Methylation","Epigenetics","Biomarker discovery","SFRP2","TFPI2","SEPT9","SDC2","qMSP","Korean population","Colorectal cancer prevention","Adenoma-carcinoma sequence","2026-01-25",{"date":298,"type":41},"2026-01-27",{"date":300,"type":23},"2026-02-10",{"date":302,"type":23},"2027-05-09",{"name":304,"class":47},"Bundang CHA Hospital",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":116},"100611238","colorectal-omics-and-ofcs-proteoglycans-coco-in-screening-and-a-diagnostic-pathway-100611238","NCT07237984","Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway","Colorectal OmiCs and Oncofetal Chondroitin Sulfate-modified Proteoglycans in Screening and Colorectal Cancer Diagnostic Pathway","COCO-S","Inclusion Criteria:\n\n* Patients planned to undergo a colonoscopy either as part of the colorectal cancer screening programme due to a positive FIT or within a 'cancer patient pathway' for CRC at one of the study sites.\n* Able to speak Danish, English, or other languages with sufficient interpretation provided by relatives.\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Patients previously included in the study\n* Patients known to be pregnant (pregnancy test not required)\n* Non-resident in Denmark.",{"count":58,"type":23},"Colorectal Cancer (CRC), or bowel cancer, is a serious disease that affects many people globally. The earlier CRC is diagnosed, the better the patient outcomes.\n\nThe problem with the current diagnostic methods is that they lead to many unnecessary endoscopies (colonoscopies). In Denmark alone, over 30,000 patients every year undergo a colonoscopy without having a serious disease. This puts a major strain on both patients and the healthcare system.\n\nThis research project aims to solve that problem. COCO-S is investigating oncofoetal chondroitin sulphate-modified proteoglycans (ofCS) to see if ofCS can be used as a novel, unique cancer marker found in the blood.\n\nofCS are special molecules that reappear in most tumour tissues. A method has been developed to detect ofCSs in a simple blood sample.\n\nInitial findings from an ongoing study are highly promising. A test using five different ofCS markers has shown very high accuracy in detecting CRC: it correctly identifies 86% of cancer cases (sensitivity) and correctly gives a \"negative\" result in 97% of cases without cancer (specificity).\n\nThe results also suggest that high ofCS levels might help clinicians detect adenomas (polyps), which are early precursors to cancer.\n\nCombining the analysis of ofCS in the blood with the existing stool test (FIT) and other promising blood markers can significantly improve patient selection for a colonoscopy.\n\nThis project will collect blood samples from patients scheduled for a colonoscopy. The blood will be analysed for ofCS and other substances to determine the combined predictive value for patients who truly require the procedure.\n\nThe findings from this project could revolutionize CRC diagnosis. By more accurately identifying patients who need a colonoscopy, the number of unnecessary, invasive procedures can be reduced while maintaining patient safety and ensuring cancer is found in time.",[134,30,316],"Inflammatory Bowel Disease (IBD)",[318,134,319,320],"Biomarker","Glycoproteins","Proteomics","2026-01-15",{"date":323,"type":41},"2026-01-20",{"date":325,"type":23},"2026-03-01",{"date":327,"type":23},"2031-12-31",{"name":329,"class":47},"Nordsjaellands Hospital",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":337,"maxAge":98,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":340,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":48},"100613033","evaluating-the-clinical-value-of-transparent-cap-assisted-second-examination-of-the-sigmoid-colon-for-improving-colorectal-adenoma-detection-rates-100613033","NCT07261319","Evaluating the Clinical Value of Transparent Cap-Assisted Second Examination of the Sigmoid Colon for Improving Colorectal Adenoma Detection Rates","Evaluating the Clinical Value of Transparent Cap-Assisted Second Examination of the Sigmoid Colon for Improving Colorectal Adenoma Detection Rates：A Single-center, Randomized Controlled Study","Inclusion Criteria:\n\n* aged 45-75 years\n\nExclusion Criteria:\n\n* Patients scheduled for therapeutic colonoscopy as postoperative surveillance after colorectal surgery, post-polypectomy follow-up, or treatment of histologically confirmed polyps\n* Patients with highly suspected or pathologically confirmed colorectal cancer\n* Patients presenting with alarm symptoms or signs (hematochezia, melena, unexplained anemia or weight loss, palpable abdominal mass, or a positive digital rectal examination)\n* Pregnant or breastfeeding women\n* Patients with gastrointestinal obstruction\n* Patients with inflammatory bowel disease, familial adenomatous polyposis, or serrated polyposis syndrome\n* Patients who have taken anticoagulants (e.g., aspirin, warfarin) within 7 days before colonoscopy or who have coagulation disorders\n* Patients currently enrolled in another clinical study or who participated in any clinical trial within the past 60 days\n* Insertion failure for any reason (e.g., scope cannot pass an obstruction, patient cannot tolerate the procedure) or colonoscopy not reaching the cecum\n* A Boston Bowel Preparation Scale (BBPS) score \\\u003C 6 at scope insertion (inadequate preparation requiring repeat bowel cleansing)\n* Use of non-guideline-recommended bowel preparation agents\n* Patients undergoing emergency colonoscopy\n* Inadequate withdrawal time (defined as a withdrawal time \\\u003C6 minutes during the first examination or \\\u003C2 minutes during the second examination)","45 Years",{"count":339,"type":23},614,[26],"A prospective, single-center, single-blind, randomized controlled study to evaluate the clinical value of transparent cap-assisted second examination of the sigmoid colon for improving colorectal adenoma detection rates",[30],[344,345,346,347],"transparent cap","adenoma detection rate","second examination","sigmoid colon","2025-11-22",{"date":350,"type":41},"2025-12-03",{"date":352,"type":23},"2025-12-15",{"date":354,"type":23},"2027-12-15",{"name":356,"class":47},"Fudan University",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":48},"100515218","performance-and-safety-of-miwendo-assisted-colonoscopy-miwendo-ii-100515218","NCT05988645","Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)","Performance and Safety of MiWEndo-assisted Colonoscopy: MiWEndo II (Pivotal Study)","Inclusion Criteria:\n\n\\- Patients with a previously detected polyp in the rectum referred for resection.\n\nThese criteria will ensure the probability of finding polyps during the explorations.\n\nAll the patients will give written informed consent.\n\nExclusion Criteria:\n\n* Patients at a high risk of having major complications as perforation or hemorrhage, suspected or proven lower gastrointestinal bleeding, non-correctable coagulopathy or anticoagulant\u002Fclopidogrel therapy during procedure, inadequate bowel cleansing.\n* ASA-IV patients.\n* Urgent colonoscopy.",{"count":365,"type":23},50,[26],"The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836)",[134,132,30,369,370,133],"Colorectal Adenomatous Polyp","Colorectal Adenocarcinoma",[372,373,374,375],"microwave imaging","colonoscopy","early diagnosis","colorectal cancer screening","2025-09-23",{"date":378,"type":41},"2025-09-29",{"date":380,"type":41},"2023-08-01",{"date":382,"type":23},"2025-12-29",{"name":384,"class":180},"MiWEndo Solutions S.L.",{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":48},"100604485","development-and-validation-of-an-artificial-intelligence-assisted-system-for-bowel-cleanliness-assessment-based-on-withdrawal-distance-weighting-100604485","NCT07150130","Development and Validation of an Artificial Intelligence-assisted System for Bowel Cleanliness Assessment Based on Withdrawal Distance Weighting","Inclusion Criteria:\n\n* Clear colonoscopy images suitable for BBPS scoring\n* Complete and clear colonoscopy videos suitable for BBPS scoring\n* Clear colonoscopy videos with a stable UPD-3 positioning system, without signal drift, disappearance, or other disruptions\n\nExclusion Criteria:\n\n* Blurred colonoscopy images\n* Colonoscopy images taken from the small intestine or outside the patient's body\n* Colonoscopy images captured during irrigation or instrument manipulation\n* Colonoscopy images obtained during chromoendoscopy\n* Colonoscopy videos that do not contain the complete withdrawal process\n* Videos in which the UPD-3 colonoscopic positioning system exhibited signal drift, disappearance, or other instability",{"count":392,"type":23},700,"To address the limitations of current AI-based systems that rely on the assumption of a \"constant withdrawal speed,\" this study proposes the integration of the UPD-3 endoscopic positioning system. By using colonoscope withdrawal videos in combination with UPD-3 imaging data as training samples, we aim to develop an AI-powered bowel cleanliness assessment system that incorporates \"withdrawal distance\" as a weighting factor. This approach is expected to yield a more reliable, objective, and clinically applicable intelligent assessment system that better aligns with real-world clinical practice and endoscopists' operational habits.",[30],[396,397,398],"Adenoma detection rate","Bowel preparation assessment","Artificial intelligence","2025-08-25",{"date":401,"type":41},"2025-09-02",{"date":403,"type":23},"2025-10-01",{"date":405,"type":23},"2028-10-01",{"name":356,"class":47},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":18,"minAge":414,"maxAge":98,"enrollmentInfo":415,"targetDuration":4,"studyType":24,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":48},"100602898","shenbai-granules-for-preventing-malignant-transformation-of-high-risk-colorectal-adenomas-100602898","NCT07129499","Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas","A Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial of Shenbai Granules for Preventing Malignant Transformation of High-Risk Colorectal Adenomas","Inclusion Criteria:\n\nAll of the following criteria must be met for enrolment:\n\n1. Aged 40-75 years, regardless of gender;\n2. High-quality colonoscopy performed within 14 days before randomisation, with initial endoscopic resection of all polyps and histological confirmation of at least one HR-CRA criteria;\n3. Complete endoscopic resection of every detected lesion;\n4. TCM syndrome differentiation of \"spleen deficiency with dampness-heat\";\n5. Signed informed consent and willingness to comply with long-term follow-up. a: High-quality colonoscopy criteria: Boston Bowel Preparation Scale score ≥ 6, cecal intubation confirmed by visualization of the ileocecal valve, and withdrawal time (excluding biopsy and polypectomy) ≥ 6 minutes.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded from the trial:\n\n1. Concomitant malignancy or history of malignancy in the digestive system;\n2. Personal or family history of familial adenomatous polyposis or hereditary non-polyposis colorectal cancer (Lynch syndrome);\n3. History of inflammatory bowel disease;\n4. Malignancy in any other organ system within 5 years before screening, except for adequately treated thyroid carcinoma, cervical carcinoma in situ, basal or squamous cell skin carcinoma, or ductal carcinoma in situ of the breast cured by radical surgery;\n5. Clinically significant organic disorders or neuro-psychiatric conditions that may affect treatment or prognosis, including but not limited to severe cardiovascular or cerebrovascular disease, autoimmune disease, motor, haematological, gastrointestinal, respiratory, immune, circulatory, reproductive, genitourinary, or endocrine disorders; coagulation abnormalities; or serious post-procedural complications (e.g., gastrointestinal bleeding, perforation, cholangitis, intra-abdominal infection, cardiorespiratory depression, mesenteric tear, or pneumoperitoneum), serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>2.5 × the upper limit of normal (ULN), or alkaline phosphatase (ALP) \\>2 × ULN;\n6. Active gastrointestinal disease, conditions predisposing to perforation, or disorders that could substantially interfere with the absorption, distribution, metabolism, or excretion of the investigational drug, such as inability to take oral medication, uncontrolled nausea or vomiting, intestinal obstruction, or chronic diarrhoea;\n7. Within 3 months before screening, continuous use for ≥3 months of ≥2 doses per week (with \\\u003C2-week interruption) of agents potentially protective against colorectal adenoma: NSAIDs (e.g., aspirin, ibuprofen, celecoxib), metformin, berberine hydrochloride, folic acid, vitamin D, selenium, calcium, systemic immunotherapy, or Chinese patent medicines or decoctions labelled for \"tonifying spleen and augmenting qi, clearing heat and eliminating dampness\". Subjects may be enrolled after a washout of 1 month or ≥5 drug half-lives, whichever is longer;\n8. Cold-pattern manifestations such as aversion to cold, cold pain in the waist\u002Fabdomen, cold extremities, or preference for hot drinks;\n9. Pregnant or lactating women, or men and women of child-bearing potential with plans to conceive during the trial or within 7 months after trial completion;\n10. Participation in another drug or device trial within 1 month or \\\u003C 5 half-lives of the investigational agent (whichever is longer) before screening, concurrent participation in another trial, or intention to participate in any other clinical trial during this trial;\n11. Known allergy or hypersensitivity to ≥ 2 drugs or foods, or hypersensitivity to any component of the trial medication;\n12. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for enrolment (e.g., poor expected compliance, cognitive impairment).","40 Years",{"count":416,"type":23},450,[26],"This multicenter, randomized, double-blind, placebo-controlled trial will enroll 450 patients with completely resected high-risk colorectal adenoma (HR-CRA), randomly assigned (1:1) to 6 months of Shenbai Granules (SBG) or placebo, followed for 3 years post-polypectomy. Primary endpoint: 3-year cumulative incidence of metachronous HR-CRA. Secondary endpoints: incidence, number, size, distribution, histology of low-risk adenomas and serrated lesions, and colorectal cancer occurrence.",[30,420,421],"High Risk","TCM","2025-08-11",{"date":424,"type":41},"2025-08-19",{"date":426,"type":23},"2025-08-15",{"date":428,"type":23},"2028-11-30",{"name":430,"class":180},"Jiangsu Famous Medical Technology Co., Ltd.",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":414,"maxAge":98,"enrollmentInfo":438,"targetDuration":4,"studyType":24,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":448,"locationsCount":48},"100602408","shenbai-granules-for-preventing-recurrence-of-low-risk-colorectal-adenomas-100602408","NCT07123116","Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas","Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas: A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nTo be eligible for this study, all of the following inclusion criteria must be met:\n\n1. Aged 40-75 years, regardless of sex;\n2. Patients with histologically confirmed high-risk adenomas undergoing initial polypectomy, with high-quality colonoscopy performed within 14 days before randomization;\n3. Complete resection of all detected lesions during colonoscopy;\n4. Meeting TCM diagnostic criteria for spleen deficiency with dampness-heat syndrome;\n5. Provision of signed informed consent and ability to comply with long-term follow-up.\n\n   1. High-quality colonoscopy is defined as: Boston Bowel Preparation Scale (BBPS) score ≥6, cecal intubation with photo-documentation and withdrawal time ≥6 minutes. If quality standards cannot be confirmed, a repeat colonoscopy is required.\n\n      \\-\n\n      Exclusion Criteria:\n\n      Subjects who meet any of the following exclusion criteria will not be enrolled in this study:\n\n1\\) Complicated with malignant tumor or having a history of malignant tumor; 2) Personal or family history of familial polyposis or hereditary nonpolyposis colorectal cancer; 3) History of inflammatory bowel disease; 4) Suffering from malignant tumors of other systems except the study disease within 5 years before screening, except for malignant tumors that have been cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery); 5) Complicated with severe organic diseases such as cardiovascular and cerebrovascular diseases, autoimmune diseases, diseases of the motor, hematological, digestive, respiratory, immune, circulatory, reproductive, urinary, or endocrine systems, or patients with neuropsychiatric diseases, abnormal coagulation function, severe postoperative complications, such as gastrointestinal bleeding, perforation, cholangitis, abdominal infection, cardiopulmonary function depression, mesenteric laceration, or pneumoperitoneum, etc., or other acute and chronic diseases that may affect treatment and prognosis; those with Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels exceeding 2.5 times the upper limit of normal, Alkaline Phosphatase (ALP) levels exceeding 2 times the upper limit of normal, or abnormal electrocardiogram results assessed by investigators as clinically significant; 6) Patients with active gastrointestinal diseases, at risk of gastrointestinal perforation, or suffering from other diseases that can significantly interfere with the absorption, distribution, metabolism, or excretion of the trial drug, such as inability to take oral drugs, uncontrolled nausea or vomiting, intestinal obstruction, chronic diarrhea due to extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.; 7) Having used the following treatments that may have a preventive effect on colorectal adenomas within 3 months before screening, for 3 consecutive months, at least 2 times a week, with an interruption time of less than 2 weeks: taking non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen, celecoxib, etc, metformin, berberine hydrochloride, folic acid, vitamin D, selenium supplements, and calcium supplements, or maintaining systemic immunotherapy, or using Chinese patent medicines based on the indications in the instructions or Chinese herbal decoctions with the effects of invigorating spleen and replenishing qi, clearing heat and eliminating dampness; those who have undergone a washout period of 1 month or 5 half-lives of the drug whichever is longer can be enrolled; 8) Those with cold syndrome such as fear of cold, cold pain in the waist and abdomen, cold limbs, and preference for hot drinks when thirsty; 9) Pregnant or lactating women, as well as men or women of childbearing age who have plans for childbearing recently or within 7 months before the study; 10) Having participated in, or currently participating in, other clinical trials of drugs or research devices within 1 month before screening or within 5 half-lives of the trial drug whichever is longer, or planning to participate in any other clinical trials during this study; 11) Allergic constitution with a history of allergy to two or more drugs or foods or known allergy to the components of the study drug; 12) Other conditions deemed unsuitable for inclusion by the investigator, such as expected poor compliance, cognitive impairment, etc.\n\n\\-",{"count":416,"type":23},[26],"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas（LRCRA）.\n\nStudy Population: Post-resection patients with low-risk colorectal adenomas and Spleen Deficiency with Dampness-Heat Syndrome per TCM criteria.\n\nSample Size: 450 subjects (1:1 randomization; 225 per arm) accounting for ≤20% dropout.\n\nStudy Hypothesis (Exploratory) ： This exploratory trial aims to evaluate the potential efficacy and safety of Shenbai Granules, a TCM formula, in reducing LRCRA recurrence. Based on preliminary data suggesting a 32.64% relative risk reduction in LRCRA recurrence at 2 years, we hypothesize that Shenbai Granules may demonstrate clinically meaningful prevention of adenoma recurrence and offer a favorable safety profile in the target TCM syndrome population. No formal statistical hypothesis is tested.\n\nStatistical Analysis Analysis Sets: mITT (primary efficacy), PPS, SS (safety). Primary Analysis: Proportion difference (Newcombe method) and χ²\u002FFisher's exact test (stratified CMH if applicable).\n\nSensitivity analyses: PPS, tipping-point imputation for missing data. Safety: Descriptive summaries of AEs\u002FSAEs (MedDRA-coded), lab abnormalities.",[30,421,442],"Low Risk","2025-08-08",{"date":445,"type":41},"2025-08-14",{"date":426,"type":23},{"date":428,"type":23},{"name":430,"class":180},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":48},"100595687","new-biomarkers-to-stratify-colorectal-cancer-referrals-100595687","NCT07035691","New bioMarkers tO straTIfy cOlorectal caNcer Referrals","Plasma Biomarkers in Stratifying Patients Referred Via the Lower Gastro-intestinal (LGI) Suspected Cancer Two-week Wait (2WW) Pathway","MOTION","Inclusion Criteria:\n\n* Adult, lower GI 2WW and or Straight to Test (STT) referral patients with suspected lower GI cancer.\n* Male and Female patients aged \\>18 years.\n* 2WW referral patients with no history of inflammatory bowel disease.\n* Performance status (ECOG 0-2; and 3 pending clinical assessment of fitness).\n* Patients with capacity to consent to the study.\n\nExclusion Criteria:\n\n* Any patients referred outside of the 2WW and or STT referral pathways with suspected Lower GI cancer or those referred as an emergency with or suspected CRC.\n* Age \\\u003C 18 years.\n* Patients not fit for standard investigations (e.g. not fit for gastroscopy, colonoscopy or CT colonography) in the 2WW pathway.\n* Patients with no capacity to consent or who declined consent for participation.\n* Patients with untreated solid organ cancers.\n* Patients with known inflammatory bowel disease.\n* Patients with documented familial type CRC.",{"count":458,"type":23},582,"The goal of this observational study is to evaluate if a blood test for circulating progastrin (hPG80) and transposable elements (TEs) can accurately predict colorectal cancer (CRC) or polyps in adult patients referred to the 2-week wait (2WW) or Straight to Test (STT) pathways for suspected lower gastrointestinal cancer.\n\nThe main questions it aims to answer are:\n\nCan plasma hPG80 levels accurately predict a diagnosis of CRC or polyps in patients undergoing standard 2WW investigations? Can transposable elements (TEs) in the plasma serve as predictive biomarkers for CRC diagnosis in these patients? What are the patient preferences for different diagnostic tests for CRC, particularly a blood-based test compared to more invasive methods?\n\nParticipants will:\n\nProvide a 20ml blood sample during a routine hospital visit for their 2WW diagnostic test (e.g., colonoscopy, CT Colon).\n\nUndergo standard clinical investigations as determined by their treating clinicians.\n\nHave their final diagnosis (cancer, polyp, or normal) correlated with their plasma hPG80 levels.\n\nFor a subset of 100 participants (25 with confirmed CRC, 75 non-cancer), have their plasma analyzed for circulating signatures using RNAseq and DNAseq.\n\nComplete an electronic post-study questionnaire to explore their preferences and experiences with different CRC diagnostic tests used within the 2WW pathway.",[461,462,30],"Colorectal Carcinoma","Polyp",[464,465,462,78,466,467,468,469,470,471,472,473],"Colorectal cancer","Cancer","Cancer surveillance","Flag symptoms","Liquid biopsy","Progastrin","Circulating biomarkers","Biomarkers","Risk stratification","Early diagnosis","2025-08-07",{"date":443,"type":41},{"date":477,"type":41},"2025-06-30",{"date":479,"type":23},"2026-10-01",{"name":481,"class":47},"Queen Mary University of London",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":116},"100484809","a-novel-oral-synbiotic-formula-in-reducing-advanced-adenoma-recurrence-and-colorectal-neoplasia-related-bacterial-gene-markers-100484809","NCT05592886","A Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers","A Multicenter, Double Blinded Randomized Controlled Trial of a Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers","Inclusion Criteria:\n\n* Subjects who have advanced colorectal neoplasia\\* removed and confirmed by histopathology;\n* They have received high quality colonoscopies before or during endoscopic resection (defined as a full colonoscopy with successful caecal intubation, and a Boston Bowel Preparation Scale ≧2 in each colonic segment) with no residual colorectal neoplasia;\n* Aged 18-90 years old;\n* Written informed consent obtained\n\n  * An advanced colorectal neoplasia is defined as an advanced adenoma, sessile serrated lesion or non-invasive colorectal cancer (stage Tis or T1a). Advanced adenoma is defined as an adenoma larger than 10mm, and\u002For with villous component ≥20%, and\u002For harboring high grade dysplasia.\n\nExclusion Criteria:\n\n* Known residual colorectal neoplasia not removed (except hyperplastic polyps);\n* Contraindications to endoscopic resection due to deep submucosal invasion (stage T1b or above);\n* Prior surgical resection of colon;\n* Personal history of hereditary polyposis syndrome or inflammatory bowel disease;\n* Known pregnancy or lactation;\n* Immunocompromised status (e.g. on immunosuppressants (except 5-aminosalicylic acid or short term use of corticosteroids \\\u003C4 weeks), on chemotherapy, bone marrow or solid organ transplant, human immunodeficiency virus, congenital immune deficiency);\n* Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);\n* Refusal to undergo surveillance colonoscopy.","90 Years",{"count":491,"type":23},649,[26],"This multicenter, double blinded randomized controlled trial aims to assess the efficacy of a novel oral synbiotic formula (SMT04) in reducing advanced adenoma recurrence and colorectal neoplasia-related bacterial gene markers after endoscopic resection of colorectal advanced neoplasia.",[133,30,134,495],"Advanced Adenoma",[497,498],"Adenoma recurrence","Bacterial marker","2025-07-29",{"date":501,"type":41},"2025-08-01",{"date":503,"type":41},"2022-12-15",{"date":505,"type":23},"2027-12-31",{"name":507,"class":47},"Chinese University of Hong Kong",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":18,"minAge":337,"maxAge":98,"enrollmentInfo":515,"targetDuration":4,"studyType":24,"phases":517,"briefSummary":518,"conditions":519,"keywords":520,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":526,"leadSponsor":528,"locationsCount":48},"100600427","transparent-cap-assisted-colonoscopy-combined-with-computer-aided-detection-in-improving-the-detection-rate-of-colorectal-adenomas-100600427","NCT07097350","Transparent Cap-Assisted Colonoscopy Combined With Computer-Aided Detection in Improving the Detection Rate of Colorectal Adenomas","Study on the Effect of Transparent Cap-Assisted Colonoscopy Combined With Computer-Aided Detection in Improving the Detection Rate of Colorectal Adenomas","Inclusion Criteria:\n\n* aged 45-75 years\n\nExclusion Criteria:\n\n* Patients scheduled for therapeutic colonoscopy as postoperative surveillance after colorectal surgery, post-polypectomy follow-up, or treatment of histologically confirmed polyps\n* Patients with highly suspected or pathologically confirmed colorectal cancer\n* Patients presenting with alarm symptoms or signs (hematochezia, melena, unexplained anemia or weight loss, palpable abdominal mass, or a positive digital rectal examination)\n* Pregnant or breastfeeding women\n* Patients with gastrointestinal obstruction\n* Patients with inflammatory bowel disease, familial adenomatous polyposis, or serrated polyposis syndrome\n* Patients who have taken anticoagulants (e.g., aspirin, warfarin) within 7 days before colonoscopy or who have coagulation disorders\n* Patients currently enrolled in another clinical study or who participated in any clinical trial within the past 60 days\n* Insertion failure for any reason (e.g., scope cannot pass an obstruction, patient cannot tolerate the procedure) or colonoscopy not reaching the cecum\n* A Boston Bowel Preparation Scale (BBPS) score \\\u003C 6 at scope insertion (inadequate preparation requiring repeat bowel cleansing)\n* Use of non-guideline-recommended bowel preparation agents\n* Patients undergoing emergency colonoscopy",{"count":516,"type":23},524,[26],"A prospective, single-center, single-blind, randomized controlled study to compare the effectiveness of transparent cap-assisted colonoscopy combined with computer-aided detection and computer-aided detection alone in improvement of adenoma detection rate",[30],[344,521,345],"computer-aided detection","2025-07-24",{"date":524,"type":41},"2025-07-31",{"date":501,"type":23},{"date":527,"type":23},"2027-08-01",{"name":356,"class":47},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":18,"minAge":414,"maxAge":98,"enrollmentInfo":535,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":48},"100589685","development-and-validation-of-microbiota-and-metabolite-based-prediction-model-for-recurrence-of-high-risk-colorectal-polyps-after-polypectomy-100589685","NCT06957626","Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy","Inclusion Criteria:\n\n* patients aged 40-75 years who undergo the colonoscopy with at least 1 advanced premalignant polyps or ≥ 3 adenoma\n\nExclusion Criteria:\n\n* patient with severe physical diseases that prevented them from adhering to the examination requirements,\n* patient with coagulopathy or other contraindications for biopsy or polypectomy,\n* patient with previous surgical procedures on the gastrointestinal tract,\n* presence of colorectal cancer or other malignant tumor at baseline\n* presence of inflammatory bowel disease or hereditary polyposis syndromes (such as family adenomatous polyposis or Lynch syndrome)\n* within 1 month before enrollment, oral antibiotics and probiotics were taken;\n* inability to provide informed consent or refusal to participate in the study.",{"count":256,"type":23},"The characteristics of the intestinal microbiota in high-risk colorectal polyp recurrence and their relationship with disease pathogenesis have not yet been fully elucidated. This study aims to analyze the microbial community characteristics in the intestinal mucosal tissue of patients after polypectomy with recurrence of colorectal polyps. Additionally, this research holds significant importance for understanding the etiology of adenoma recurrence and develop a microbiota and metabolite-based predicting tool.",[132,538,30],"Colorectal Cancer Recurrent","2025-06-29",{"date":541,"type":41},"2025-07-01",{"date":543,"type":41},"2023-04-25",{"date":545,"type":23},"2026-04-30",{"name":547,"class":47},"Peking Union Medical College Hospital",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":254,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":558,"briefSummary":559,"conditions":560,"keywords":562,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":48},"100590698","cold-snare-versus-cold-forceps-polypectomy-for-small-lesions-100590698","NCT06970808","Cold Snare Versus Cold Forceps Polypectomy for Small Lesions","Cold SNAre Versus Cold forcePS Polypectomy for Small Colorectal Lesions (Cold-SNAPS): a Multicenter Randomized Trial","Cold-SNAPS","Inclusion Criteria:\n\n* Patients aged ≥ 18 years;\n* Ability to provide informed consent;\n* Presence of at least one colorectal polypoid\u002Fnon-polypoid lesion \\\u003C 10 mm\n\nExclusion Criteria:\n\n* Primary or secondary coagulopathy;\n* Improper interruption of dual antiplatelet therapy and\u002For antiplatelet therapy with P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor) and\u002For anticoagulant therapy;\n* Chronic inflammatory bowel diseases;\n* Inpatients undergoing colonoscopy;\n* Colonoscopy as part of regional colorectal cancer screening;\n* Pregnancy or breastfeeding",{"count":557,"type":23},312,[26],"The goal of this clinical trial is to compare the efficacy and the safety of a new device for cold forceps polypectomy (CFP)- a special jumbo forceps- to cold snare polypectomy (CSP) for small colorectal lesions, without adding peri- or post-procedural risks to the patient.\n\nThe main questions it aims to answer are:\n\n* Does the cold forceps guarantee a complete endoscopic resection rate?\n* How many adverse events could the jumbo forceps reduce in comparison to CSP?\n* Does the lesion retrieval rate increase?\n* Does the polypectomy duration decrease? Participants will be randomized to one or to the other group when a polypoid or non-polypoid lesion is identified. If multiple polyps are found in the same patient, they will be removed using the same polypectomy technique.\n\nIf polypectomy cannot be performed using the indicated technique, a crossover will be done according to the best practice of care principles.",[30,561],"Colorectal Lesions",[563,137,564],"Cold forceps polypectomy","Cold snare polypectomy","2025-05-06",{"date":567,"type":41},"2025-05-14",{"date":569,"type":23},"2025-12",{"date":571,"type":23},"2027-12",{"name":573,"class":47},"Azienda USL Modena",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":254,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":48},"100539753","circulating-tumor-dna-in-patients-summoned-for-colonoscopy---a-liquid-biopsy-for-detection-characterization-individualized-treatment-and-follow-up-of-colorectal-cancer-100539753","NCT06307938","Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer","CoLiQ","Inclusion Criteria:\n\n* Patient ≥ 18 years old summoned for colonoscopy\n* Patient able to understand and sign written informed consent\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years old\n* Patient unable to understand or give written informed consent\n* Patient unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and\u002For otherwise considered by the investigator as unlikely to complete the study",{"count":582,"type":23},3000,"CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.",[134,30],[318,468,586],"ctDNA","2025-04-25",{"date":589,"type":41},"2025-04-30",{"date":591,"type":41},"2025-03-10",{"date":593,"type":23},"2028-05",{"name":595,"class":47},"Helse Nord-Trøndelag HF",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":254,"sex":18,"minAge":19,"maxAge":98,"enrollmentInfo":603,"targetDuration":4,"studyType":24,"phases":605,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":4},"100587138","advanced-adenoma-detection-with-3d-imaging-device-during-colonoscopy-100587138","NCT06924489","Advanced Adenoma Detection With 3D Imaging Device During Colonoscopy","Effect of 3-Dimensional Imaging Device on Advanced Adenoma Detection During Colonoscopy: A Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18-75 years;\n* Patients with indications for colonoscopy and receiving diagnostic colonoscopy, without history of inflammatory bowel disease, colorectal cancer, polypectomy or polyposis syndromes;\n* Signing the written informed consent;\n\nExclusion Criteria:\n\n* Patients with polyposis syndromes (e.g., Peutz-Jeghers syndrome, Cronkhite-Canada syndrome, familial adenomatous polyposis \\[FAP\\], Lynch syndrome, etc.);\n* Patients with a history of colorectal polypectomy and pathological diagnosed as adenoma;\n* Patients with a history of colorectal adenocarcinoma or alarming symptoms;\n* Patients with a history of inflammatory bowel disease;\n* Patients with mental illness or severe functional disorder who cannot cooperate with colonoscopy;\n* Patients with severe cardiopulmonary insufficiency;\n* Patients with severe coagulation disorders or high bleeding risk (platelets \\\u003C50×10⁹\u002FL, INR \\>1.5; discontinuation of antithrombotic drugs should follow the 2012 Japanese Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment and the2017 Appendix on Anticoagulants Including Direct Oral Anticoagulants;\n* Patients with severe electrolyte imbalances;\n* Patients with acute peritonitis or suspected intestinal perforation;\n* Patients with toxic megacolon;\n* Patients with stage 3 or higher hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg);\n* Patients with untreated severe abdominal hernia, intestinal obstruction;\n* Patients with intestinal strictures of any cause;\n* Pregnancy and lactation.",{"count":604,"type":23},1566,[26],"The goal of this clinical trial is to learn if 3-dimensional (3D) imaging device works to identify patients with high risk adenomas during colonoscopy to guide proper follow-up strategy. It will also learn about the safety of 3-dimensional (3D) imaging device. The main questions it aims to answer are:\n\nDoes 3-dimensional (3D) imaging device improve the identification of patients with high risk adenomas? What adverse events do participants experience during colonoscopy? Researchers will compare 3-dimensional (3D) imaging device to traditional 2-dimensional (2D) imaging device to see if 3-dimensional (3D) imaging device works to improve high risk adenoma identification.\n\nParticipants will:\n\nUndertake colonoscopy examination using 3-dimensional (3D) imaging device or 2-dimensional (2D) imaging device. Be followed-up to 30 days to record potential colonoscopy-relevant adverse events.",[30,66],"2025-04-04",{"date":610,"type":41},"2025-04-11",{"date":612,"type":23},"2025-06-01",{"date":614,"type":23},"2026-07-01",{"name":616,"class":47},"Xijing Hospital of Digestive Diseases",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":254,"sex":18,"minAge":337,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":4},"100488128","clinical-performance-of-the-mainz-biomed-colorectal-cancer-screening-test-for-colorectal-cancer-and-advanced-adenoma-100488128","NCT05636085","Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma","Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for the Detection of Colorectal Cancer and Advanced Adenoma in an Average Risk Population","reconAAsense","Inclusion Criteria:\n\n1. Subject is any sex and ≥45 years of age\n2. Subject must be advised to have or be scheduled for a screening colonoscopy\n3. Subject is at average risk for colorectal cancer according to the United States Preventive Services Task Force (USPSTF) guidelines, including:\n\n   * no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease\n   * no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer including:\n\n     * Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease\n     * Familial adenomatous polyposis (also referred to as \"FAP\", including attenuated FAP)\n     * Hereditary non-polyposis colorectal cancer syndrome (also referred to as \"HNPCC\" or \"Lynch Syndrome\")\n     * Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis\n     * Cronkhite Canada Syndrome\n4. Subject can understand the study procedures and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form\n5. Subject is able and willing to provide stool samples within ninety (90) days before the colonoscopy procedure\n6. Subject is able and willing to undergo a colonoscopy after providing a stool sample\n\nExclusion Criteria:\n\n1. Subject had any precancerous findings on most recent colonoscopy.\n2. Subject has a history of abnormal imaging suggesting colorectal cancer (e.g., colonography, MRI, CT, barium enema)\n3. Subject has a history of any of the following cancers: oral, head and neck, lung, esophagus, gastric, biliary\u002Fliver, pancreatic, small bowel, or appendiceal\n4. Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals\n\n   * High-sensitivity fecal occult blood test or fecal immunochemical test within the previous twelve (12) months\n   * sDNA-FIT test within the previous thirty-six (36) months\n5. Subject has had a colonoscopy in the previous nine (9) years\n6. Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease\n7. Indication for colonoscopy due to overt rectal bleeding (e.g., hematochezia or melena) within the previous thirty (30) days\n8. Subject has any condition that in the opinion of the investigator should preclude participation in the study",{"count":626,"type":23},15000,"This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.",[134,133,132,30],"2025-03-03",{"date":631,"type":41},"2025-03-05",{"date":633,"type":23},"2025-12-31",{"date":635,"type":23},"2027-09-01",{"name":637,"class":180},"Mainz Biomed",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":278,"enrollmentInfo":646,"targetDuration":4,"studyType":24,"phases":648,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":662,"locationsCount":48},"100571064","evaluation-of-a-cam-system-for-colorectal-polyp-size-measurement-100571064","NCT06715384","Evaluation of a CAM System for Colorectal Polyp Size Measurement","Performance Evaluation of a Computer-aided Measuring System for Colorectal Polyp Size Measurement: a Prospective Study","CAM","Inclusion Criteria:\n\n1. Adults aged 18-75, any gender; 76-85 years eligible case-by-case based on health status.\n2. Colonoscopy screening, surveillance, or diagnostic participants.\n3. Informed consent obtained.\n\nExclusion Criteria:\n\n1. Anticoagulant use (e.g., aspirin, warfarin) within 7 days prior to colonoscopy or coagulopathy.\n2. Inflammatory bowel disease.\n3. Aronchick score \\>3 at entry.\n4. Incomplete Case Report Form (CRF) data.\n5. Emergency colonoscopy.\n6. Pregnancy or lactation.\n7. Gastrointestinal obstruction.\n8. Refusal to participate.",{"count":647,"type":23},168,[26],"Accurate polyp size measurements are essential for risk stratification, selection of polypectomy techniques, and surveillance interval assignments. Evidence indicated that the clinical implementation of artificial intelligence is an optimal tool to improve the measurement of polyps during colonoscopy. This study aimed to evaluate the performance of a computer-aided measuring (CAM) system (EndoDASS) and compare its accuracy with routine sizing methods during real-time colonoscopy.",[132,30],[652,653,654,137,655],"Artificial Intelligence","Polyp Size","Deep Learning","Depth Map","2025-02-15",{"date":658,"type":41},"2025-02-19",{"date":660,"type":41},"2024-12-15",{"date":589,"type":23},{"name":663,"class":47},"Changhai Hospital"]